Northwire Canada EditionWednesday, September 2, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4424.40 +0.6% SILVER 65.74 +0.6% COPPER 6.62 +0.3% ABI 0.080 +6.7% GZD 0.060 +0.0% OOR 0.050 +0.0% CGM 0.210 +10.5% VCG 1.55 +7.6% SLR 0.810 −24.3% AEF 0.140 +3.7% GTC 1.05 +11.7% PEMC 0.065 +0.0% CTGO 27.26 +4.3% PUMA 0.120 +4.3% TRR 0.345 +7.8% OGN 4.85 +1.0% ECU 1.79 +4.7% MGMA 0.125 +0.0% GOLD 4424.40 +0.6% SILVER 65.74 +0.6% COPPER 6.62 +0.3% ABI 0.080 +6.7% GZD 0.060 +0.0% OOR 0.050 +0.0% CGM 0.210 +10.5% VCG 1.55 +7.6% SLR 0.810 −24.3% AEF 0.140 +3.7% GTC 1.05 +11.7% PEMC 0.065 +0.0% CTGO 27.26 +4.3% PUMA 0.120 +4.3% TRR 0.345 +7.8% OGN 4.85 +1.0% ECU 1.79 +4.7% MGMA 0.125 +0.0%
Technical Study Routine +

Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project

Voyageur Pharmaceuticals secures a permit to bulk sample the Frances Creek barite deposit despite liquidity constraints and dilution concerns.

By The Northwire Desk — AI Analysis Jun 10, 2026 · 07:31 VM · 0.09 Voyageur Pharmaceuticals Ltd.
Executive Summary
  • Voyageur Pharmaceuticals submitted a Multi-Year Area-Based (MYAB) Notice of Work to the BC Ministry of Mining and Critical Minerals for its Frances Creek barite project.
  • The application covers a 76.8-hectare work area and authorizes Year 1 extraction of 2,000 tonnes of high-grade barite ore.
  • The extraction aims to validate a proprietary dry densimetric concentration and acid leach process for pharmaceutical-grade barium contrast agents.
  • The program includes geotechnical drilling to finalize pit and waste rock designs, fulfilling the final data requirement to complete a NI 43-101 Final Feasibility Study.
  • The project builds on a 2022 Preliminary Economic Assessment (PEA) projecting a $464M pre-tax NPV and 168% IRR.
  • Recent testing confirms barite purity exceeds 97.5% USP standards, averaging 98.8% BaSO4.
  • The submission follows the company's strategic roadmap to build a vertically integrated North American supply chain for barium and iodine contrast media.
Material Impact
  • The permit submission is a logical, expected progression following the March 2026 strategic roadmap and the $5M private placement closed on June 5, 2026.
  • It de-risks the Final Feasibility Study by providing necessary geotechnical and bulk sampling data.
  • The 2,000-tonne test extraction will generate material for pilot plant validation, bridging the gap between exploration and commercial production.
  • While the PEA economics are attractive, they remain preliminary. The actual impact on the stock is muted by the company's severe liquidity position and the incremental nature of the news.
  • The news aligns with management's stated goal to complete bankable feasibility studies in H2 2026, but does not alter the immediate cash burn or dilution trajectory.
VM · Price
Company Overview
  • Voyageur Pharmaceuticals is a Canadian pre-revenue company developing vertically integrated barium and iodine contrast media for medical imaging.
  • The flagship project is the Frances Creek barite deposit in British Columbia, which hosts an indicated resource of 214,800 tonnes at 35.2% BaSO4 and an inferred resource of 134,200 tonnes at 33.9% BaSO4.
  • The company aims to become the sole vertically integrated manufacturer of both barium and iodine contrast agents in North America, securing supply chains and offering cost-effective imaging drugs.
  • The company has initiated FDA 505(b)(2) submissions for its barium product suite and plans to file a generic iodine NDA in late 2026.
  • The company recently signed a collaboration with Bayer for up to $2.35M in milestone funding for an iodine extraction plant in Oklahoma.
Read the original news release →

More from Voyageur Pharmaceuticals Ltd.

Aug 10, 2026 · 07:00

Voyageur Pharmaceuticals validates its domestic iodine supply chain for contrast media through successful pilot extraction operations.

Production / Operations Jun 23, 2026 · 16:00

Voyageur Pharmaceuticals is advancing its North American supply chain for early-stage radiology drug development.

Technical Study Jun 18, 2026 · 17:01

Voyageur Pharmaceuticals advances its U.S. manufacturing footprint despite facing liquidity constraints and maintaining a pre-revenue status.

Production / Operations Jun 05, 2026 · 18:30

Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption

Financings May 28, 2026 · 16:45

Voyageur Pharmaceuticals Seeks Capital Amidst Price Collapse and Dilution Concerns

Financings May 01, 2026 · 18:55

Voyageur Pharmaceuticals Cuts Offering Price Amidst Dilution Concerns as Capital Raise Targets FDA Milestones

Financings